ArriVent BioPharma (AVBP) Retained Earnings (2023 - 2026)

ArriVent BioPharma has disclosed Retained Earnings across 4 years of filings, most recently posting -$270000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$270000.0, down 1488.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$270000.0 (down 1488.24% YoY), and the FY2025 annual result was -$404.6 million, down 69.78% from the prior year.
• Retained Earnings came in at -$270000.0 for Q1 2026 at ArriVent BioPharma, up from -$404.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$17000.0 in Q1 2025 to a low of -$404.6 million in Q4 2025.
• The 4-year median for Retained Earnings is -$186.2 million (2024), against an average of -$176.0 million.
• Across the five-year window, Retained Earnings soared 99.99% in 2025 and slumped 1488.24% in 2026, its largest moves.
• ArriVent BioPharma's Retained Earnings stood at -$157.8 million in 2023, then plunged by 50.99% to -$238.3 million in 2024, then slumped by 69.78% to -$404.6 million in 2025, then soared by 99.93% to -$270000.0 in 2026.
• The last three Retained Earnings figures came in at -$270000.0 (Q1 2026), -$404.6 million (Q4 2025), and -$369.1 million (Q3 2025), per Business Quant data.